ArticlemBio2025
Validation of human sensory neurons derived from inducible pluripotent stem cells as a model for latent infection and reactivation by herpes simplex virus 1.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Herpes simplex virus pUL56 abolishes neuronal activity by removing voltage-gated ion channels from the plasma membrane.Science advances · 2026Article
- Optimization of lytic herpes simplex virus infection in human induced pluripotent stem cell-derived cortical neurones.The Journal of general virology · 2026Article
- Counteracting FOX proteins epigenetically control the herpesvirus lytic-latent balance.Nature communications · 2026Article
- Chromatin Regulation of HSV Gene Transcription.Viruses · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Herpes simplex virus 1 (HSV-1) undergoes primary acute lytic replication in mucosal epithelial cells and then spreads to establish latent infection in peripheral neurons including sensory and autonomic neurons. Latent HSV-1 reactivates to cause recurrent cold sores but can also cause more severe disease including keratitis and encephalitis. Animal models have been used extensively to study HSV-1 latent infection, while human sensory neuronal systems have been difficult to establish or make scalable. To address neuron-intrinsic mechanisms of HSV-1 latent infection, we developed a protocol to rapidly differentiate human-inducible pluripotent stem cells (hiPSCs) into sensory neurons. The differentiated neurons are excitable and express functional ion channels. We established conditions for latent infection with HSV-1 in these cells that show i) no infectious virus, ii) reduced lytic gene expression, iii) efficient latency-associated transcript expression, and iv) viral heterochromatin. Latent HSV-1 can be reactivated by previously known stimuli including forskolin and PI3Ki. Therefore, this scalable human iPSC-derived sensory neuron system is a promising model to explore mechanisms of HSV-1 latent infection in human neurons. IMPORTANCE: Herpes simplex viruses are prevalent human pathogens that cause significant morbidity and mortality in neonates and adults. They undergo acute infection in the mucosae and spread to peripheral neurons including sensory and autonomic neurons, where they establish lifelong latent infection. Reactivation from latency leads to recurrent infection and disease, including central nervous system infection that can be life-threatening. Experimental studies of HSV latency have mostly been conducted in animals, which may differ from the human situation. In this study, we establish a system for differentiation of human-inducible pluripotent stem cells into sensory neurons and for latent infection and reactivation by herpes simplex virus 1. This system will enable studies of the mechanism of HSV latent infection in human sensory neurons and therapeutic approaches to curtail it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.